IL17A and infection: However, careful monitoring is warranted for specific OIs such as herpes zoster infection following JAKi treatment, mucocutaneous candidiasis following anti-IL-17 treatment, and <i>Mycobacterium tuberculosis</i> infection following anti-TNF treatment.